Michael Gelband’s Rhythm Pharmaceuticals RYTM Stock Holding History

Michael Gelband’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.79M	Buy	61,147 +43,372	+244%	+$3.92M	0.04%	402
2026 Q1	$1.55M	Sell	17,775 -57,366	-76%	-$5.58M	0.01%	868
2025 Q4	$8.04M	Buy	+75,141	New	+$7.97M	0.06%	319
2024 Q1	–	Sell	-40,197	Closed	-$1.85M	–	1906
2023 Q4	$1.85M	Sell	40,197 -112,246	-74%	-$3.54M	0.01%	607
2023 Q3	$3.5M	Buy	152,443 +136,762	+872%	+$3.06M	0.03%	475
2023 Q2	$259K	Sell	15,681 -37,977	-71%	-$685K	﹤0.01%	1599
2023 Q1	$957K	Buy	+53,658	New	+$1.35M	0.01%	1150
2022 Q1	–	Sell	-15,475	Closed	-$154K	–	2612
2021 Q4	$154K	Buy	15,475 +3,874	+33%	+$43.5K	﹤0.01%	1880
2021 Q3	$152K	Sell	11,601 -3,343	-22%	-$51.1K	﹤0.01%	1834
2021 Q2	$293K	Buy	+14,944	New	+$310K	﹤0.01%	1758
2020 Q3	–	Sell	-13,483	Closed	-$301K	–	2168
2020 Q2	$301K	Buy	+13,483	New	+$263K	0.01%	1321
2019 Q2	–	Sell	-19,596	Closed	-$537K	–	1299
2019 Q1	$537K	Buy	+19,596	New	+$563K	0.04%	311

Other funds holding RYTM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Michael Gelband's RYTM Position: Q2 2026 in Review

Michael Gelband increased its Rhythm Pharmaceuticals (RYTM) stake by 244% in Q2 2026, buying an estimated $3.92M and bringing the position to 61,147 shares worth $6.79M. The position accounts for 0.04% of the portfolio, ranked #402.

Michael Gelband first reported a position in RYTM in Q1 2019 and has held it in 12 quarters since. The position peaked at $8.04M in Q4 2025. 300 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

Michael Gelband held 61,147 shares of Rhythm Pharmaceuticals worth $6.79M as of Q2 2026.
Michael Gelband bought 43,372 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $3.92M.
Rhythm Pharmaceuticals made up 0.04% of Michael Gelband's portfolio in Q2 2026, its #402 holding.
Michael Gelband first reported a position in Rhythm Pharmaceuticals in Q1 2019 and has held it in 12 quarters since.
Michael Gelband's Rhythm Pharmaceuticals position peaked at $8.04M in Q4 2025.
300 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.